India Pfizer Approval

US health authorities on Monday approved Pfizer's Covid-19 booster shot for children as young as 12, and reduced the wait time between initial vaccination and an extra dose from six months to five, for all ages.

Pfizer CEO Albert Bourla has said that his company hope to finalise a deal with the Indian government on the approval for the company's Covid vaccine. A few days ago, NITI Aayog member D VK Paul, too, had said the same thing.

"I hope very soon we will finalise an agreement with the government," said Pfizer's CEO Albert Bourla

To speed up approvals for Pfizer and Moderna in India, the government may grant a major concession requested by them - indemnity from liability.

Pfizer said on Monday it told the Indian government that there was no concern over the safety of its COVID-19 vaccine, as India insists on small local trials for foreign shots despite a record surge in infections and shortage of doses.

Pfizer is in discussions with the Indian government seeking an "expedited approval pathway" for its COVID-19 vaccine, its CEO Albert Bourla said on LinkedIn on Monday, announcing a donation of medicines worth more than $70 million.

Just two days before pharma major Pfizer announced withdrawal of its application for emergency use authorisation of its COVID-19 vaccine in India, an expert panel of the country's drugs regulatory authority had recommended against granting such approval to the firm at this stage, officials told news agency Press Trust of India on Friday.

Pfizer Inc will pursue its request for India to approve its COVID-19 vaccine if the government commits to buying shots, the US drugmaker told Reuters on Monday, even as global supplies tighten.

The World Health Organization (WHO) listed Pfizer and BioNTech's Covid-19 shot for emergency use on December 31 as it sought to accelerate vaccination in the developing world, which is badly lagging Western countries

Any vaccine maker, including Pfizer Inc, which has sought emergency-use authorisation for its COVID-19 shot in India, must conduct a local "bridging" safety and immunogenicity study to be considered for the country's immunisation programme, a senior government official told Reuters.

US pharma giant Pfizer, whose Covid vaccine has yet be approved, told NDTV on Monday that it had been "unable to participate in previous meetings (to present safety and efficacy data) due to extremely short notice" and time zone differences

Applications for the emergency use approval for the coronavirus vaccines filed by the Serum Institute of India, Bharat Biotech and Pfizer are being taken up once again for consideration by a government-appointed panel of experts today.

Applications for the emergency use approval for the coronavirus vaccines filed by the Serum Institute of India, Bharat Biotech and Pfizer were taken up for consideration by a government-appointed panel of experts on Wednesday.

An expert panel will tomorrow review the request by three pharmaceutical firms - the Serum Institute of India, Pfizer and Bharat Biotech - to approve emergency use of their coronavirus vaccines in India, sources told NDTV.

American pharmaceutical firm Pfizer, which has asked the DCGI (Drugs Controller General of India) for emergency approval of its coronavirus vaccine, has said it is prepared to address a key challenge in the distribution of its vaccine - ultra-cold storage.

US health authorities on Monday approved Pfizer's Covid-19 booster shot for children as young as 12, and reduced the wait time between initial vaccination and an extra dose from six months to five, for all ages.

Pfizer CEO Albert Bourla has said that his company hope to finalise a deal with the Indian government on the approval for the company's Covid vaccine. A few days ago, NITI Aayog member D VK Paul, too, had said the same thing.

"I hope very soon we will finalise an agreement with the government," said Pfizer's CEO Albert Bourla

To speed up approvals for Pfizer and Moderna in India, the government may grant a major concession requested by them - indemnity from liability.

Pfizer said on Monday it told the Indian government that there was no concern over the safety of its COVID-19 vaccine, as India insists on small local trials for foreign shots despite a record surge in infections and shortage of doses.

Pfizer is in discussions with the Indian government seeking an "expedited approval pathway" for its COVID-19 vaccine, its CEO Albert Bourla said on LinkedIn on Monday, announcing a donation of medicines worth more than $70 million.

Just two days before pharma major Pfizer announced withdrawal of its application for emergency use authorisation of its COVID-19 vaccine in India, an expert panel of the country's drugs regulatory authority had recommended against granting such approval to the firm at this stage, officials told news agency Press Trust of India on Friday.

Pfizer Inc will pursue its request for India to approve its COVID-19 vaccine if the government commits to buying shots, the US drugmaker told Reuters on Monday, even as global supplies tighten.

The World Health Organization (WHO) listed Pfizer and BioNTech's Covid-19 shot for emergency use on December 31 as it sought to accelerate vaccination in the developing world, which is badly lagging Western countries

Any vaccine maker, including Pfizer Inc, which has sought emergency-use authorisation for its COVID-19 shot in India, must conduct a local "bridging" safety and immunogenicity study to be considered for the country's immunisation programme, a senior government official told Reuters.

US pharma giant Pfizer, whose Covid vaccine has yet be approved, told NDTV on Monday that it had been "unable to participate in previous meetings (to present safety and efficacy data) due to extremely short notice" and time zone differences

Applications for the emergency use approval for the coronavirus vaccines filed by the Serum Institute of India, Bharat Biotech and Pfizer are being taken up once again for consideration by a government-appointed panel of experts today.

Applications for the emergency use approval for the coronavirus vaccines filed by the Serum Institute of India, Bharat Biotech and Pfizer were taken up for consideration by a government-appointed panel of experts on Wednesday.

An expert panel will tomorrow review the request by three pharmaceutical firms - the Serum Institute of India, Pfizer and Bharat Biotech - to approve emergency use of their coronavirus vaccines in India, sources told NDTV.

American pharmaceutical firm Pfizer, which has asked the DCGI (Drugs Controller General of India) for emergency approval of its coronavirus vaccine, has said it is prepared to address a key challenge in the distribution of its vaccine - ultra-cold storage.